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Transfer of genetically engineered macrophages into
the glomerulus
MASANORI KITAMURA and TAMAs S. SUTO
Glomendar Engineering Unit, Department of Medicine, University College London Medical School, London, England, United Kingdom
Monocytes/macrophages have been regarded as "blackguards"
in the generation of glomerular injury [1]. This is largely depen-
dent on descriptive observation based on histopathological anal-
yses [2—5]. Using manipulations for macrophage depletion, several
studies have suggested the crucial role of macrophages during the
course of experimental glomerulonephritis [6—10]. However, cur-
rently it is unclear whether macrophages alone induce certain
molecular/cellular events in the normal glomerulus and, if so,
what kind of cellular function is responsible for the pathophysio-
logical action. To answer these questions, there are two major
hurdles: (i) macrophages must be accumulated in the normal
glomerulus, and (ii) certain function of macrophages need to be
selectively reinforced or deleted. Towards achieving these goals, a
possible challenge would be to manipulate macrophages at a
genetic level and transfer them into the glomerulus. In this report,
we describe a novel technique that allows us to create glomeruli
populated with genetically engineered macrophages.
Methods
Establishment of genetically engineered macrophages
A normal alveolar macrophage cell line NR8383 [11] derived
from a Sprague-Dawley rat was purchased from American Type
Culture Collection (Rockville, MD, USA). The cells were main-
tained in Dulbecco's modified Eagle's medium/Ham's F-12
(DME-F12; GIBCO BRL, Gaithersburg, MD, USA) supple-
mented with 100 U/ml of penicillin G, 100 .tg/ml of streptomycin,
0.25 pg/mI of amphotericin B and 10 to 15% fetal calf serum
(FCS, GIBCO BRL).
In the presence of 10 jig/mI Polybrene (Sigma Immunochemi-
cals, St. Louis, MO, USA), NR8383 cells were exposed to 1:1
diluted conditioned medium from a helper-free packaging cell
line fIE/BAG [12] that produces a replication-incompetent BAG
virus. This retroviral vector transduces a bacterial 13-galactosidase
gene (lacZ) and a neomycin phosphotransferase gene (neo) under
the control of a Moloney murine leukemia virus long terminal
repeat (LTR) and a simian virus 40 promoter [13]. Stable
infectants were selected in the presence of neomycin analogue
G418 (Sigma; 500 jig/mI), and BAGMAC cells were established.
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Expression of f3-galactosidase was examined by Northern blot
analysis and 5-bromo-4-chloro-3-indolyl -D-galactopyranoside
(X-gal) assay [14]. To confirm that the cellular phenotype was
unaffected after the transduction, morphological and adhesive
properties of BAGMAc" cells were examined by light micros-
copy. Lipopolysaccharide (LPS) responses were also studied and
compared to those of parental NR8383 cells. For this purpose,
NR8383 cells and BAGMACNR cells were stimulated with or
without 1 jig/mI of LPS (E. coil 0111:B4; Sigma) for 18 hours, and
expression of matrix metalioproteinase-9 (MMP-9) and IL-1J3 was
investigated by Northern blot analysis [15, 16].
Transfer of engineered macrophages into the glomerulus
BAGMAC cells (1 >< 106) previously treated with or without 1
jig/mI LPS for 14 to 24 hours were delivered into normal rat
glomeruli (10 Sprague-Dawley rats, 250 to 350 g) via renal artery
injection [12]. After the cell transfer, both kidneys were immedi-
ately removed and processed for glomerular isolation by a con-
ventional sieving method [17]. To examine cell transfer efficiency,
isolated glomeruli were subjected to X-gal assay [12, 14]. In brief,
glomeruli were fixed in 0.5% glutaraldehyde, 2 m'vi MgCl2, and
1.25 mrvi EGTA in phosphate buffered saline (PBS) at 4°C
overnight and incubated at 37°C for one hour in a reaction buffer
containing 1 mg/mi X-gal (Sigma), 20 mM K3Fe(CN)6, 20 mM
K4Fe(CN)6 3H20, 2 mrvi MgCl2, 0.01% sodium desoxycholate
and 0.02% NP-40 in PBS. More than 100 glomeruli were ran-
domly selected, and the percentages of X-gal-positive glomeruli
were determined by light microscopy.
Neomycin subtraction method
Unmodified glomerular cells are susceptible to neomycin
whereas BAGMAcNR cells transduced with neo are resistant to this
drug. Using this difference, it is possible to subtract contribution
of resident cells from total responses of BAGMAcNRcontaining
glomeruli. Using MMP-9 as an indicator molecule, we tested the
dose-dependent effect of G418 on the function of glomerular cells
and BAGMACNR macrophages. Isolated normal rat glomeruli (5 X
10) and LPS-stimulated BAOMAc cells (5 x 10) were incu-
bated for 24 hours in 1% FCS/DME-F12 containing 50 to 500
jig/mI G418. Northern and zymographic analyses were performed
on MMP-9 expression as described below.
Gelatin zymography
Gelatin zymography was performed as reported previously [15,
18]. In brief, aliquots of conditioned media (5 jid)were mixed with
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5 il of 2x sample buffer (4% SDS, 0.005% bromophenol blue,
and 20% glycerol in 0.5 M Tris-HC1, pH 6.8) and applied to 10%
acrylamide gels containing 0.1% gelatin. After electrophoresis,
SDS was removed from the gels by incubation in 2.5% Triton
X-100 at room temperature for 30 minutes. The gels were then
incubated overnight at 37°C in a developing buffer containing 0.2
M NaCl, 5 ms CaC12, and 0.02% Brij 35 in 50 mivi Tris-HCI (pH
7.6). Gels were stained in a solution containing 30% methanol,
10% glacial acetic acid and 0.5% Coomassie G250 and destained
in the same solution without dye.
Northern blot analysis
After glomerular isolation, 0.5 to 1 X i04 glomeruli from each
kidney were immediately stored at —80°C. The remaining ito 2 X
i04 glomeruli were incubated in the absence or presence of 200
g/ml G418 in 0.5 to 1% FCS for 18 to 24 hours and then stored
at —80°C.
Total RNA was extracted from BAGMAc cells and isolated
glomeruli (0.5 to 1 X 10) by a single-step method [191 and
subjected to Northern analysis, as described before [161. In brief,
RNA samples were electrophoresed on 1.2% agarose gels con-
taining 10% formaldehyde and transferred onto nitrocellulose
membranes (Schleicher & Schuell, Dassel, Germany). For hybrid-
ization, a bacterial -galactosidase cDNA [13], a mouse MMP-9
eDNA [15], a mouse IL-113 cDNA [16] and a rat stromelysin
cDNA [20] were labeled with 32P-dCTP using a random priming
method. The membranes were hybridized with probes at 65°C
overnight in a solution containing 4 X SSC (600 m sodium
chloride, 60 m sodium citrate), 5x Denhardt's solution, 10%
dextran sulfate, 50 tg/ml herring sperm DNA and 50 jg/ml
poly(A). The membranes were washed four times in 4 X SSCI
0.1% SDS at 50°C and exposed to Kodak XAR films at —80°C.
Data presentation
All experiments were repeated two to five times with similar
results, and representative data are shown. Densitometric analysis
was performed using the computerized program, NIH Image.
Results
NR8383 macrophages were transduced with a replication-
incompetent retrovirus BAG that introduces lacZ and neo. The
established BAGMACN cells expressed a 7 to 8 kb transgene
transcript, conceivably a lacZ-neo fusion mRNA driven by LTR
(Fig. IA). X-gal assay revealed that parental NR8383 cells did not
exhibit any f3-galactosidase activity whereas the transduced cells
expressed high levels of the exogeneous enzyme (Fig. IB). All the
cells examined were positive for X-gal staining. BAGMAC cells
showed a round shape and a peculiar adhesive property (half
attached, half detached) similarly to the parental NR8383 cells
(data not shown). Northern blot analysis revealed that, in re-
sponse to LPS, BAGMACNR cells expressed MMP-9 and IL-113 at
same mRNA levels as those in NR8383 cells (Fig. iC).
We previously reported that cultured mesangial cells injected
into the renal circulation accumulated in the glomerulus. Using a
similar technique, established BAGMAC macrophages were
delivered into the glomeruli of adult rat kidneys via the renal
circulation. X-gal assay revealed that in the injected kidneys
77.9 5.7% (mean SE, 10 rats) of isolated glomeruli were
positive for X-gal staining (Fig. 2A). This percentage was main-
tained in culture for at least several days (our unpublished data).
13-Galactosidase activity was detected neither in glomeruli isolated
from contralateral kidneys (Fig. 2B) nor in glomeruli transferred
with parental NR8383 cells (not shown).
A
28 -
1 8S-
B
C
b
— + — ÷
l -
3-actin
Fig. 1. Establishment and characterization of BAGMACN macrophages.
NR8383 rat macrophages were transduced with a replication-incompetent
retrovirus BAG that introduces a f3-galactosidase gene (lacZ) and a
neomycin phosphotransferase gene (neo). Stably transduced cells were
selected by neomycin analogue G418, and BAGMAC? cells were estab-
lished. A. Northern blot analysis of lacZ expression. A 3.1 kb fragment of
lacZ eDNA derived from pBAG [13] was used as a probe. Position of
ribosomal RNAs (28S and 18S) is indicated on the left. B. Detection of
3-galactosidase activity by 5-bromo-4-chloro-3-indolyl 3-D-galactopyrano-
side (X-gal) assay. C. Responses of BAGMACNR cells to lipopolysaccharide
(LPS). Parental NR8383 cells and BAoMAcr cells were stimulated with
(+) or without (—) 1 j.g/ml of LPS for 18 hours, and expression of matrix
metalloproteinase-9 (MMP-9) and IL-ljJ was examined by Northern blot
analysis. Expression of -actin is shown as a loading control.
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Fig. 2. In vivo transfer Of BAGMAC' macrophages into the rat glomerulus. BAGMAc cells (1 >< l0) were delivered into rat glomeruli via renal artery
injection. Both kidneys were removed and processed for glomerular isolation, and glomeruli were subjected to X-gal assay. A. Glomeruli isolated from
the injected left kidney. B. Glomeruli from the uninjected right kidney (light microscopy >< 100).
For the purpose of selective abrogation of resident cells from
the "chimeric" glomeruli, a neomycin subtraction method was
established. Using MMP-9 as an indicator, susceptibility of gb-
merular cells and neo-transduced BAGMACNR cells to G418 was
examined. Zymographic analysis on conditioned media revealed
that unmodified glomeruli constitutively expressed MMP-9. This
basal expression was markedly depressed by G418 in a dose-
dependent fashion (Fig. 3A, upper row). A total of 200 .tg/ml of
G418 reduced the MMP-9 production to 21% of the level of
untreated cells (Fig. 3B, open circle). In contrast, the expression
of MMP-9 by activated BAGMACNR cells was not affected by 50 to
200 .tg/ml of G418 (Fig. 3A, lower row). The highest dosage (500
.tg/ml) slightly depressed the MMP-9 expression (81% vs. un-
treated control 100%; Fig. 3B, closed circle). Similarly, in North-
ern blot analysis, concentrations of G418 higher than 50 g/ml
abrogated MMP-9 expression by isolated glomeruli whereas that
of BAGMAC" cells was unaffected (Fig. 3C). These results
suggested the utility of G418 for subtracting contribution of
resident cells from total function of chimeric glomeruli.
The matrix metalloproteinase stromelysin is induced in mesan-
gial cells in response to the macrophage-secretable proinfiamma-
tory cytokine, IL-1j3 [21]. Using this molecule as an indicator, we
investigated how activated macrophages can modulate the expres-
sion of certain gene in the normal glomerulus. LPS-stimulated
BAGMAC cells were transferred into the glomerulus, and ex-
pression of stromelysin was examined by Northern analysis.
Immediately after the cell transfer (do), stromelysin mRNA was
not detectable in isolated glomeruli. However, after ex vivo
incubation of these glomeruli (dl), expression of stromelysin was
substantially induced (Fig. 4A). Slight induction of stromelysin
was also observed in glomeruli isolated from uninjected kidneys.
To confirm that stromelysin was up-regulated in resident glomer-
ular cells but not in the transferred macrophages, the neomycin
subtraction method was utilized. In the presence of 200 .tg/ml
G418, the induction of stromelysin in the macrophage-containing
glomeruli was completely abolished (Fig. 4B). These results
evidenced that activated macrophages recruited into normal
gbomeruli stimulated resident cells to the induction of stromelysin
within the glomerular microenvironment.
Discussion
Communication between resident glomerular cells and macro-
phages is a crucial event during the generation of glomerular
injury [1]. Macrophages are pleiotypic cells that produce a variety
of potentially injurious molecules including cytokines, proteolytic
enzymes, reactive oxygen/nitrogen species and bioactive lipids
[23]. Histology-based studies have elucidated a link between
macrophage infiltration and histopathological changes in human
glomerular diseases [2—5 1. The pathological importance of mac-
rophages has been investigated more extensively in several exper-
imental glomerulonephritis. Using these models in combination
with manipulations for macrophage depletion, a close correlation
between macrophage accumulation and onset of glomerular in-
jury has been established [6—10]. Despite a body of accumulative
literature, currently it is unclear whether macrophages alone can
induce certain molecular and cellular events in the normal
gbomerulus. Furthermore, information is limited regarding the
links between certain function of macrophages and structural,
functional and/or molecular alterations in the glomerulus. To
address these issues, we developed a strategy to deliver genetically
modified macrophages into the glomerulus. After injecting into
the renal artery, engineered macrophages populated in 78% of
glomeruli. When pre-stimulated macrophages were transferred,
substantial induction of stromelysin was observed in the glomer-
ulus. To our knowledge, this provides the first direct evidence that
activated macrophages have an ability to induce expression of
certain gene in the normal glomerulus.
When both macrophages and glomerular cells are able to
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Fig. 3. Neomycin subtraction assays. Using MMP-9 as an indicator mole-
cule, susceptibility of resident glomerular cells and engineered macro-
phages to G418 was tested. Isolated normal glomeruli (5 X 10) and
LPS-stimulated BAGMAc cells (5 x 10; I jrg/ml LPS for 18 hr) were
incubated for 24 hours in 1% FCS/DME-F12 containing 50 to 500 g/ml
of G4I8. MMP-9 expression was examined by zymography and northern
analysis. A. Gelatin zymography on conditioned media. B. Densitometric
analysis of MMP-9 expression. Symbols are: (0) isolated glomeruli; •)
BAGMAd° cells. C. Northern blot analysis of MMP-9 expression.
express certain molecule, it is required to identify the cell type
responsible for the expression in chimeric glomeruli. For this
purpose the neomycin subtraction method has been developed.
This is based on the difference in susceptibility to the neomycin
analogue G418 between glomerular cells and neo-transduced
macrophages. As shown in Figure 3, G418 did not affect function
of activated BAGMACNR cells whereas it abolished the activity of
unmodified glomeruli. In the chimeric glomeruli transferred with
BAGMACN cells, the induction of stromelysin was abrogated by
G418. The activated macrophages recruited into normal glomer-
uli thus stimulated resident cells to the induction of stromelysin
within the local microenvironment. This result showed the utility
of G418 for selective ablation of endogenous expression of
molecules in the chimeric glomeruli.
Stromelysin/transin is a member of matrix-degrading metallo-
proteinases that play a crucial role in the metabolism of extracel-
lular matrix. Tightly controlled expression of this enzyme is
supposed to be essential for embryogenesis/organogenesis and
Stromelysin
Fig. 4. Induction of stromelysin in macrophage-containing glomeruli in the
absence or presence of G418. After the transfer of activated BAGMAC'°
cells, isolated glomeruli (0.5 to 1 x 10) from both kidneys were separately
incubated ex viva in the absence (A) or presence (B) of G418 (200 JLglml)
for 24 hours. Expression of stromelysin was examined by Northern blot
analysis before (dO) or after (dl) the incubation. This study was repeated
five times with similar results. Abbreviations are: RK(—), uninjected right
kidney; LK(+), injected left kidney.
wound healing, and its uncontrolled expression is associated with
certain pathologies such as tumor invasion/metastasis, inflamma-
tion and atherosclerosis [24—26]. Stromelysin is a multipotent
matrix degrader, that is, it degrades collagens, glycoproteins and
proteoglycans [271, all of which are components of the glomerular
extracellular matrix. Overexpression of stromelysin possibly in-
duces aberrant breakdown of glomerular matrix (mesangial ma-
trix and basement membrane) and thereby contributes to struc-
tural and functional alteration [281. We previously reported that
rat mesangial cells have an ability to express stromelysin in
response to the macrophage-secretable proinflammatory cyto-
kine, IL-1f3 [211. When stromelysin was overexpressed via genetic
manipulation, mesangial cells exhibited an altered phenotype,
that is, enhanced mitogenesis and migration [20], suggesting its
pathological implication. However, currently information is very
limited regarding whether stromelysin is inducible in the glomer-
ulus, and if so, what kind of pathological setting is responsible for
the induction. The present study has provided one answer to this
question. In the glomerulus where activated macrophages are
present, stromelysin can be elicited in the resident glomerular
cells.
Application of this method for glomerular research seems to be
enormous. The cell transfer studies would allow to investigate how
unstimulated or stimulated macrophages affect the normal gb-
merular structure and function. Even 24 hours after the cell
injection, 58.6 3.8% (mean Se, 7 rats) of isolated gbomeruli
retained substantial number of viable BAGMACNR cells (our
unpublished data), suggesting the utility of this approach for in
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vivo experimental settings. The cx vivo experimental system com-
bined with the neomycin subtraction method will be useful to
explore molecular events of the macrophage-accumulating gb-
merulus in more detail. Stable genetic inactivation of certain
functions of macrophages via an antisense, decoy, ribozyme or
transdominant negative strategy will be useful to elucidate the
exact function of macrophage-associated molecules in gbomerular
pathophysiology. In combination with disease models it would
also enable clarification of links between certain macrophage
functions and particular pathological conditions.
As we previously reported, gene transfer into the glomerulus
using a cell vector system is feasible [12, 14, 15, 18]. In this regard,
the genetically engineered macrophage could be an attractive
gene transfer vector. Circulating monocytes/macrophages have an
ability to accumulate at inflammatory sites of organs [29]. Holds-
worth and Neale previously reported accumulation of cultured
macrophages in nephritic glomeruli following intravenous injec-
tion [9]. Furthermore, after a peak of acute response, macro-
phages relocate from the local sites to draining lymph nodes [29,
30]. If the production of endogenous injurious mediators by
macrophages is controllable, these peculiar properties would be
advantageous as a gene transfer vector, especially for delivering
therapeutically-relevant molecules to affected sites with appropri-
ate timing and duration.
Genetic engineering of macrophages would be an attractive
strategy for glomerular research and therapy, but generally this
cell type is not susceptible to transfection. Although several
methods have been developed for this purpose [31—35], only few
reports have demonstrated the establishment of stably transfected
or transduced macrophages [36—37]. This is mainly due to their
unproliferative property and prominent ability to degrade incor-
porated macromolecules. The former is especially a crucial prob-
lem in cell transfer studies where a substantial number of homog-
enous macrophages are required. To circumvent these problems,
the present study utilized a rat macrophage line, NR8383 [11].
This cell line, originally established from pulmonary alveolar
macrophages, proliferates in response to FCS and exhibits a
number of properties typical of differentiated macrophages.
Those include zymosan ingestion, nonspecific esterase activity, Fc
receptors expression, and production of IL-i, metalloproteinase,
nitric oxide and H202 in response to stimuli [11, 38—40]. Unlike
other several macrophage-like cells derived from tumors, NR8383
cells originated from the normal tissue. Although the majority of
macrophage lines have been established in mice, this cell line
derived from the rat. This is advantageous for glomerular re-
search, because, in contrast to other species, various experimental
manipulations and disease models are available in rats. Using
retrovirus-mediated gene transfer, the present study successfully
transduced foreign genes into the NR8383 macrophages. Other
conventional gene transfer protocols using a calcium phosphate
co-precipitation method or cationic liposomes were found to be
inefficient for this purpose (M. Kitamura, unpublished data). The
established cells, conferred with the reporting function and neo-
mycin resistance, showed typical features of macrophages not
unlike the parental NR8383 cells. The BAGMAC cells described
here are supposed to be useful for investigating in situ cross-talk
between macrophages and gbomerular cells in normal and a
variety of pathological circumstances.
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